POSCOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
POSITRON CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.70+0.15 (+9.68%)
Close on Oct 19, 2026
- Market cap
- $55.84M
- P/E (TTM)
- –
- Dividend yield
- –
POSITRON CORP revenue by segment
By business segment
| Revenue | TTM Q3 15 | TTM Q2 15 | TTM Q1 15 | TTM Q4 14 | TTM Q3 14 | TTM Q2 14 | TTM Q1 14 | TTM Q4 13 | TTM Q3 13 | TTM Q2 13 | TTM Q1 13 | TTM Q4 12 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical equipment and service | $1.23M | $1.31M | $1.34M | $1.45M | $1.68M | $1.64M | $1.72M | $1.63M | $1.52M | $1.54M | $2.33M | $2.79M | 99.0% | -27.0% |
| Radiopharmaceuticals | $12.00K | $17.00K | $17.00K | $17.00K | $5.00K | $0 | $0 | $0 | $12.00K | $12.00K | $12.00K | $12.00K | 1.0% | +140.0% |
| Operating income | TTM Q3 15 | TTM Q2 15 | TTM Q1 15 | TTM Q4 14 | TTM Q3 14 | TTM Q2 14 | TTM Q1 14 | TTM Q4 13 | TTM Q3 13 | TTM Q2 13 | TTM Q1 13 | TTM Q4 12 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unallocated | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $14.00K | $14.00K | $14.00K | -$6.00K | – |
| Radiopharmaceuticals | -$410.00K | -$412.00K | -$451.00K | -$508.00K | -$789.00K | -$877.00K | -$877.00K | -$862.00K | -$942.00K | -$782.00K | -$885.00K | -$1.03M | -48.0% |
| Medical equipment and service | -$999.00K | -$1.53M | -$1.98M | -$2.08M | -$2.50M | -$2.44M | -$2.43M | -$2.49M | -$2.25M | -$2.48M | -$2.82M | -$3.69M | -60.0% |
By product or service
By region
From the segment and revenue-disaggregation notes of Positron's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.